Somatic hypermutation

Revision as of 18:58, 19 June 2009 by LBiller (talk | contribs)
(diff) ← Older revision | Latest revision (diff) | Newer revision → (diff)
Jump to navigation Jump to search

WikiDoc Resources for Somatic hypermutation

Articles

Most recent articles on Somatic hypermutation

Most cited articles on Somatic hypermutation

Review articles on Somatic hypermutation

Articles on Somatic hypermutation in N Eng J Med, Lancet, BMJ

Media

Powerpoint slides on Somatic hypermutation

Images of Somatic hypermutation

Photos of Somatic hypermutation

Podcasts & MP3s on Somatic hypermutation

Videos on Somatic hypermutation

Evidence Based Medicine

Cochrane Collaboration on Somatic hypermutation

Bandolier on Somatic hypermutation

TRIP on Somatic hypermutation

Clinical Trials

Ongoing Trials on Somatic hypermutation at Clinical Trials.gov

Trial results on Somatic hypermutation

Clinical Trials on Somatic hypermutation at Google

Guidelines / Policies / Govt

US National Guidelines Clearinghouse on Somatic hypermutation

NICE Guidance on Somatic hypermutation

NHS PRODIGY Guidance

FDA on Somatic hypermutation

CDC on Somatic hypermutation

Books

Books on Somatic hypermutation

News

Somatic hypermutation in the news

Be alerted to news on Somatic hypermutation

News trends on Somatic hypermutation

Commentary

Blogs on Somatic hypermutation

Definitions

Definitions of Somatic hypermutation

Patient Resources / Community

Patient resources on Somatic hypermutation

Discussion groups on Somatic hypermutation

Patient Handouts on Somatic hypermutation

Directions to Hospitals Treating Somatic hypermutation

Risk calculators and risk factors for Somatic hypermutation

Healthcare Provider Resources

Symptoms of Somatic hypermutation

Causes & Risk Factors for Somatic hypermutation

Diagnostic studies for Somatic hypermutation

Treatment of Somatic hypermutation

Continuing Medical Education (CME)

CME Programs on Somatic hypermutation

International

Somatic hypermutation en Espanol

Somatic hypermutation en Francais

Business

Somatic hypermutation in the Marketplace

Patents on Somatic hypermutation

Experimental / Informatics

List of terms related to Somatic hypermutation

Please Take Over This Page and Apply to be Editor-In-Chief for this topic: There can be one or more than one Editor-In-Chief. You may also apply to be an Associate Editor-In-Chief of one of the subtopics below. Please mail us [1] to indicate your interest in serving either as an Editor-In-Chief of the entire topic or as an Associate Editor-In-Chief for a subtopic. Please be sure to attach your CV and or biographical sketch.

Overview

Somatic hypermutation (or SHM) is a mechanism inside cells that is part of the way the immune system adapts to new foreign elements if it is confronted with (for example, microbes). It serves to diversify the receptors the immune system uses to recognize foreign elements (antigens), and allows the immune system to adapt its response to new threats during the lifetime of an organism.[1] Somatic hypermutation involves a programmed process of mutation affecting the variable regions of immunoglobulin genes. Unlike many other types of mutation, SHM affects only individual immune cells, and the mutations are not transmitted to offspring.[1]

Mistargetted somatic hypermutation is currently under investigation as a possible mechanism in the development of B-cell lymphomas. [2]

Targets

When a B cell recognizes an antigen, it is stimulated to divide (or proliferate). During proliferation, the B cell receptor locus undergoes an extremely high rate of somatic mutation, that is at least 105-106 fold greater than the normal rate of mutation across the genome.[1] The mutations that occur are mainly single base substitutions, with occasional insertions and deletions and occur at “hotspots” located throughout DNA that encodes the immunoglobulin variable region.[3] This directed hypermutation allows for the selection of B cells that express immunoglobulin receptors possessing an enhanced ability to recognize and bind a specific foreign antigen.

Mechanism

Chemical structure of cytosine
Chemical structure of uracil

Experimental evidence supports the view that the mechanism of SHM involves deamination of cytosine to uracil in DNA by an enzyme called Activation-Induced (Cytidine) Deaminase, or AID.[4][5] A cytosine:guanine pair is thus directly mutated a to a uracil:guanine mismatch. Uracil residues are not normally found in DNA, therefore, to maintain the integrity of the genome most of these mutations must be repaired by high-fidelity DNA mismatch repair enzymes. The uracil bases are removed by the repair enzyme, uracil-DNA glycosylase.[5] Error-prone DNA polymerases are then recruited to fill in the gap and create mutations.[6]

The synthesis of this new DNA involves error-prone DNA polymerases, which often introduce mutations either at the position of the deaminated cytosine itself or neighboring base pairs. During B cell division the immunoglobulin variable region DNA is transcribed and translated. The introduction of mutations in the rapidly-proliferating population of B cells ultimately culminates in the production of thousands of B cells, possessing slightly different receptors and varying specificity for the antigen, from which the B cell with highest affinities for the antigen can be selected. The B cells with the greatest affinity will then be selected to differentiate into long-lived plasma cells producing antibody and memory B cells contributing to enhanced immune responses upon reinfection.[1]

The hypermutation process also utilizes cells that auto-select against the 'signature' of an organism's own cells. It is hypothesized that failures of this auto-selection process may also lead to the development of an auto-immune response.

See also

References

  1. 1.0 1.1 1.2 1.3 Oprea, Mihaela (1999) Antibody Repertoires and Pathogen Recognition: The Role of Germline Diversity and Somatic Hypermutation University of Leeds.
  2. Odegard VH, Schatz DG. Targeting of somatic hypermutation. Nat Rev Immunol 2006; 6(8): 573-83. PMID 16868548
  3. Li, Ziqiang, Caroline J. Woo1, Maria D. Iglesias-Ussel, Diana Ronai and Matthew D. Scharff. (2004) The generation of antibody diversity through somatic hypermutation and class switch recombinationFull Text (html) Genes & Development 18:1-11.
  4. Diaz, Marilyn Somatic Hypermutation National Institute of Environmental Health Sciences.
  5. 5.0 5.1 Larson, Erik D and Nancy Maizels (2004) Transcription-coupled mutagenesis by the DNA deaminase AID Full Text (html) Genome Biol.; 5(3):211.
  6. Neuberger, Michael "Immunity and DNA deamination MRC Laboratory of Molecular Biology

External links

Template:SIB

de:somatische Hypermutation he:היפרמוטציה של תאי הגוף

Template:WikiDoc Sources